The effectiveness of SAA to detect α-synucleinopathy, coupled with the central role ascribed to α-synuclein pathology in DLB, has led to the recent development of biological frameworks to define Lewy body diseases anchored primarily on the presence of seed-competent α-synuclein on SAA [12, 13]. The gene discussed is SNCA; the disease is Lewy body dementia.